Videos

Angela M. DeMichele, MD, professor of Medicine and Epidemiology, University of Pennsylvania, discusses the biology of triple negative breast cancer and the significant role of DNA repair.

Hendrik-Tobias Arkenau, MD, PhD, founding medical director, executive medical director, Sarah Cannon Research Institute UK, gives an overview of the JAVELIN trial in gastric cancer. He also discusses the safety profile of avelumab.

Metastatic Prostate Cancer with Charles Ryan, MD and William K. Oh, MD

Stanley Yap, MD, assistant professor, urologic oncology, UC Davis Comprehensive Cancer Center, discusses needed improvements and next steps in neoadjuvant chemotherapy for muscle-invasive bladder cancer.

Mark Ball, MD, chief urology resident, Johns Hopkins University School of Medicine, discusses the clinical, pathological, and genomic profiles of exceptional responders to anti-PD-1 therapy in renal cell carcinoma.

Fred Schumacher, PhD, MPH, associate professor, Case Western Reserve University, discusses a study that highlights the optimal use of the identification of genetic risk factors in prostate cancer, as well as the biology of developing prostate cancer.

Metastatic Prostate Cancer with Charles Ryan, MD and William K. Oh, MD

David A. Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses the important considerations and challenges in using immune checkpoint inhibitors to treat patients with glioblastoma.

Norman E. Sharpless, MD, professor of Medicine and Genetics, chair, the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center, UNC School of Medicine, discusses the significance of the ipilimumab/nivolumab findings from the CheckMate-069 trial for melanoma.

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses how depth of response plays an important role in the treatment of colorectal cancer.